Ezetimibe TEVA Indications/Uses

Primary hypercholesterolaemia: Ezetimibe TEVA, co-administered with an HMG-CoA reductase inhibitor (statin) is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia who are not appropriately controlled with a statin alone.
Ezetimibe TEVA monotherapy is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia in whom a statin is considered inappropriate or is not tolerated.
Prevention of Cardiovascular Events: Ezetimibe TEVA is indicated to reduce the risk of cardiovascular events (see PHARMACOLOGY: Pharmacodynamics under Actions) in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when added to ongoing statin therapy or initiated concomitantly with a statin.
Homozygous Familial Hypercholesterolaemia (HoFH): Ezetimibe TEVA co-administered with a statin, is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g. LDL apheresis).
Homozygous Sitosterolaemia (Phytosterolaemia): Ezetimibe TEVA is indicated as adjunctive therapy to diet for use in patients with homozygous familial sitosterolaemia.